Das SRL Exhibits New Lab Solutions at MEDLAB 2017
|
By LabMedica International staff writers Posted on 09 Feb 2017 |

Image: The AP22 IF BLOT ELITE system (Photo courtesy of Das SRL).
Das SRL, which designs, manufactures, and markets analyzers and automated equipment for application in immuno-enzimatic, immuno-fluorescence, and clinical chemistry, exhibited its AP22 IF BLOT ELITE system and NEO BIL Plus bilirubinometer at MEDLAB 2017.
Italy-based Das SRL offers systems for automated ELISA process on micro-plates and immunofluorescence on slides; readers and washers for laboratories using micro-titre plates or micro-strips; programmable semi-automated photometers for clinical chemistry analysis; and neonatal bilirubinometers for bilirubin monitoring using centrifuged whole blood samples.
The company’s AP22 IF BLOT ELITE is a fully automated system for ELISA and IFA and BLOT methods. The instrument is capable of running 2 ELISA micro-plates with 8 tests on line, 16 IFA slides or 24 BLOT strips. It can perform full automation for the Dot/Western Blot, from sample dilution and dispensing, reagent dispensing, incubation, and strip washing to dot imaging processing and assessment for each strip.
Also on display at the 4-day exhibition held from February 6-9, 2017, in Dubai, UAE was Das SRL’s NEO BIL Plus, an advanced version of traditional bilirubinometers, designed to analyze the 'total bilirubin' through a microcapillary tube. NEO BIL Plus features a special reading system, which can carry out a precise sample measurement of both bilirubin and interferentials at the same point of the capillary using a small quantity of serum and without any reagents.
Italy-based Das SRL offers systems for automated ELISA process on micro-plates and immunofluorescence on slides; readers and washers for laboratories using micro-titre plates or micro-strips; programmable semi-automated photometers for clinical chemistry analysis; and neonatal bilirubinometers for bilirubin monitoring using centrifuged whole blood samples.
The company’s AP22 IF BLOT ELITE is a fully automated system for ELISA and IFA and BLOT methods. The instrument is capable of running 2 ELISA micro-plates with 8 tests on line, 16 IFA slides or 24 BLOT strips. It can perform full automation for the Dot/Western Blot, from sample dilution and dispensing, reagent dispensing, incubation, and strip washing to dot imaging processing and assessment for each strip.
Also on display at the 4-day exhibition held from February 6-9, 2017, in Dubai, UAE was Das SRL’s NEO BIL Plus, an advanced version of traditional bilirubinometers, designed to analyze the 'total bilirubin' through a microcapillary tube. NEO BIL Plus features a special reading system, which can carry out a precise sample measurement of both bilirubin and interferentials at the same point of the capillary using a small quantity of serum and without any reagents.
Latest MEDLAB 2017 News
- AXA Diagnostics Showcases SkyLAB752 ELISA Analyzer
- Norma Diagnostika Showcases Icon Hematology Analyzers at MEDLAB
- AITbiotech Exhibits abTES Molecular Diagnostics Assays at MEDLAB 2017
- Binding Site Unveils Optilite Protein System
- Priorclave Showcases Energy-Efficient Lab Autoclaves in Dubai
- Diatron Exhibits Abacus 5 and Aquila Hematology Analyzers
- DRG Group Presents New Analyzer and ELISAs at Dubai Lab Exhibition
- Beckman Coulter Exhibits New Lab Solutions in Dubai
- Siemens Healthineers Showcases Latest Diagnostic Innovations
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
In myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), molecular blood testing for minimal residual disease (MRD) can detect signs of impending relapse before clinical symptoms emerge.... Read more
Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
Metastatic prostate cancer remains a major treatment challenge, particularly when deciding whether to add chemotherapy to hormonal therapy. In the United States, about 334,000 men are diagnosed with prostate... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel





.jpg)



